DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).

Hirva Mamdani(Wayne State University), Shadia I. Jalal(Indiana University Health), Rebecca Feldman(Caris Life Sciences (United States)), Ari M. Vanderwalde(West Cancer Center), Mohammad Asad(Wayne State University), Stephen V. Liu(Georgetown University), Alexander I. Spira(Virginia Cancer Specialists), Nagla Fawzy Abdel Karim(Augusta University), Yanis Boumber(Fox Chase Cancer Center), C. Patrick(Penn State Milton S. Hershey Medical Center), Jorge J. Nieva(University of Southern California), Jerry Yongqiang Chen(Singapore General Hospital), Abdul Rafeh Naqash(Oklahoma City University), Seongho Kim(Wayne State University), Hossein Borghaei(Fox Chase Cancer Center), Yahya Ibrahim(Wayne State University), David C. Portnoy(Campbell Clinic)
Journal of Clinical Oncology
May 20, 2019
10.1200/jco.2019.37.15_suppl.9100
Cited by 13

Related Papers

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818